Product
|
ENA-78/CXCL5, Human(HEK 293-expressed)
|
Cat#
|
101-27-208A
|
Sequence
|
AGPAAAVLRE LRCVCLQTTQ GVHPKMISNL QVFAIGPQCS
KVEVVASLKN GKEICLDPEA PFLKKVIQKI LDGGNKEN
|
Unit/Weight
|
5 μg
|
Unit Price
|
$32.00
|
Description
|
Epithelial-derived neutrophil-activating peptide 78 (ENA-78) is a small cytokine belonging to the CXC chemokine family. It is produced following stimulation of cells with the inflammatory cytokines interleukin-1 or tumor necrosis factor-alpha. Expression of ENA-78 has also been observed in eosinophils, and can be inhibited with the type II interferon,IFN-γ. ENA-78 stimulates the chemotaxis of neutrophils possessing angiogenic properties. It plays a role in reducing sensitivity to sunburn pain in some subjects, and could be a potential target used to understand more about pain in other inflammatory conditions. ENA-78 is well known to have chemotactic and activating functions on neutrophils, mainly during acute inflammatory responses. It can signal through the CXCR2 receptor.
Recombinant ENA-78/CXCL5 produced in 293 cells is a single polypeptide chain containing 78 amino acids. rhENA-78/CXCL5 has a molecular mass of 8.5 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at Pepmic.
|
Molecular Weight
|
8.5 kDa, observed by reducing SDS-PAGE.
|
Purity
|
> 98% as analyzed by SDS-PAGE.
|
Storage
|
Lyophilized recombinant human ENA-78/CXCL5 remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, human ENA-78/CXCL5 should be stable up to 1 week at 4°C or up to 2 months at -20°C.
|